Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene open-label extension study in flare-ups of fibrodysplasia ossificans progressiva
2014-002496-28Phase 2Unknown
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palovarotene in fibrodysplasia ossificans progressiva (FOP) (2 cohorts), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Annualized change in new heterotopic ossification volume and Comparison with NHS historical data. Status: unknown.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2014-002496-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002496-28.